A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors

Description

The purpose of this study is to find out whether 68Ga-PSMA-11 PET/CT is effective in assessing tumor uptake (tumor activity seen in cancerous tissue) in participants with high-grade glioma/HGG or brain metastases.

Conditions

High-grade Glioma, Brain Metastases, Brain Metastases, Adult

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to find out whether 68Ga-PSMA-11 PET/CT is effective in assessing tumor uptake (tumor activity seen in cancerous tissue) in participants with high-grade glioma/HGG or brain metastases.

An Investigator-Initiated Study to Evaluate PSMA Expression in Patients With High-Grade Gliomas or Brain Metastases With 68Ga-PSMA-11 PET

A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors

Condition
High-grade Glioma
Intervention / Treatment

-

Contacts and Locations

Basking Ridge

Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States, 07920

Middletown

Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States, 07748

Montvale

Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States, 07645

Commack

Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack, New York, United States, 11725

Harrison

Memorial Sloan Kettering Westchester (Consent only), Harrison, New York, United States, 10604

New York

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States, 10065

Uniondale

Memorial Sloan Kettering Nassau (Consent Only), Uniondale, New York, United States, 11553

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Ability to understand and the willingness to sign (or their legally acceptable representative (LAR) must sign) a written informed consent document
  • * Adults ≥ 18 years old
  • * Suspicion for or histologically or cytologically confirmed and previously treated HGG or brain metastases from a primary extracranial malignancy
  • * Lesion size ≥ 1 cm (for the lesion to be biopsied)
  • * ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
  • * Planned to undergo biopsy/resection of brain lesion
  • * Inability to undergo a PET scan (e.g., claustrophobia or noncompatible implant in case PET/MR is performed)
  • * Pregnant or nursing female. All women of childbearing potential must have a documented negative serum or urine pregnancy test \<1 week before study.
  • * Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiacarrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • * Patients with severe allergy to both iodinated and gadolinium contrast.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Simone Krebs, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2027-01-05